Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

Coupled electrophysiological, hemodynamic, and cerebrospinal fluid oscillations in human sleep.

Fultz NE, Bonmassar G, Setsompop K, Stickgold RA, Rosen BR, Polimeni JR, Lewis LD.

Science. 2019 Nov 1;366(6465):628-631. doi: 10.1126/science.aax5440.

PMID:
31672896
2.

How Culture Is Understood in Faculty Development in the Health Professions: A Scoping Review.

Lewis LD, Steinert Y.

Acad Med. 2020 Feb;95(2):310-319. doi: 10.1097/ACM.0000000000003024. Review.

PMID:
31599755
3.

Model-based physiological noise removal in fast fMRI.

Agrawal U, Brown EN, Lewis LD.

Neuroimage. 2020 Jan 15;205:116231. doi: 10.1016/j.neuroimage.2019.116231. Epub 2019 Oct 4.

4.

Tumor pharmacokinetics and pharmacodynamics of the CDK4/6 inhibitor ribociclib in patients with recurrent glioblastoma.

Miller TW, Traphagen NA, Li J, Lewis LD, Lopes B, Asthagiri A, Loomba J, De Jong J, Schiff D, Patel SH, Purow BW, Fadul CE.

J Neurooncol. 2019 Sep;144(3):563-572. doi: 10.1007/s11060-019-03258-0. Epub 2019 Aug 9.

PMID:
31399936
5.

An Inhibitor of Fatty Acid Synthase Thioesterase Domain with Improved Cytotoxicity against Breast Cancer Cells and Stability in Plasma.

Lupien LE, Dunkley EM, Maloy MJ, Lehner IB, Foisey MG, Ouellette ME, Lewis LD, Pooler DB, Kinlaw WB, Baures PW.

J Pharmacol Exp Ther. 2019 Oct;371(1):171-185. doi: 10.1124/jpet.119.258947. Epub 2019 Jul 12.

PMID:
31300609
6.

The effects of lapatinib on cardiac repolarization: results from a placebo controlled, single sequence, crossover study in patients with advanced solid tumors.

Coker SA, Hurwitz HI, Sharma S, Wang D, Jordaan P, Zarate JP, Lewis LD.

Cancer Chemother Pharmacol. 2019 Aug;84(2):383-392. doi: 10.1007/s00280-019-03880-9. Epub 2019 Jun 11.

PMID:
31187169
7.

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2019 Mar 14;7(1):73. doi: 10.1186/s40425-019-0559-3.

8.

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF, Carducci M, Kollmannsberger C, Rini BI, Heng DYC, Knox J, Voss MH, Spratlin J, Berghorn E, Yang L, Hammers HJ.

J Immunother Cancer. 2018 Oct 22;6(1):109. doi: 10.1186/s40425-018-0420-0. Erratum in: J Immunother Cancer. 2019 Mar 14;7(1):73.

9.

A transient cortical state with sleep-like sensory responses precedes emergence from general anesthesia in humans.

Lewis LD, Piantoni G, Peterfreund RA, Eskandar EN, Harrell PG, Akeju O, Aglio LS, Cash SS, Brown EN, Mukamel EA, Purdon PL.

Elife. 2018 Aug 10;7. pii: e33250. doi: 10.7554/eLife.33250.

10.

SAP102 regulates synaptic AMPAR function through a CNIH-2-dependent mechanism.

Liu M, Shi R, Hwang H, Han KS, Wong MH, Ren X, Lewis LD, Brown EN, Xu W.

J Neurophysiol. 2018 Oct 1;120(4):1578-1586. doi: 10.1152/jn.00731.2017. Epub 2018 Aug 1.

11.

Stimulus-dependent hemodynamic response timing across the human subcortical-cortical visual pathway identified through high spatiotemporal resolution 7T fMRI.

Lewis LD, Setsompop K, Rosen BR, Polimeni JR.

Neuroimage. 2018 Nov 1;181:279-291. doi: 10.1016/j.neuroimage.2018.06.056. Epub 2018 Jun 20.

12.

Hierarchy in disruption of large-scale networks across altered arousal states.

Lewis LD, Akeju O.

Br J Anaesth. 2017 Oct 1;119(4):566-568. doi: 10.1093/bja/aex297. No abstract available.

13.

The effects of lapatinib on CYP3A metabolism of midazolam in patients with advanced cancer.

Koch KM, Dees EC, Coker SA, Reddy NJ, Gainer SD, Arya N, Beelen AP, Lewis LD.

Cancer Chemother Pharmacol. 2017 Dec;80(6):1141-1146. doi: 10.1007/s00280-017-3470-y. Epub 2017 Nov 2.

PMID:
29098381
14.

Cell cycle perturbation induced by gemcitabine in human tumor cells in cell culture, xenografts and bladder cancer patients: implications for clinical trial designs combining gemcitabine with a Chk1 inhibitor.

Montano R, Khan N, Hou H, Seigne J, Ernstoff MS, Lewis LD, Eastman A.

Oncotarget. 2017 Jun 28;8(40):67754-67768. doi: 10.18632/oncotarget.18834. eCollection 2017 Sep 15.

15.

Standing in the Shifting Sands of Molecular Targeting and Precision Medicine Is the Oasis of 21st-Century Oncology Therapeutics.

Lee L, Lewis LD.

J Clin Pharmacol. 2017 Oct;57 Suppl 10:S7-S10. doi: 10.1002/jcph.1011. No abstract available.

PMID:
28921639
16.

Challenges faced when identifying patients for combination immunotherapy.

Ernstoff MS, Gandhi S, Pandey M, Puzanov I, Grivas P, Montero A, Velcheti V, Turk MJ, Diaz-Montero CM, Lewis LD, Morrison C.

Future Oncol. 2017 Aug;13(18):1607-1618. doi: 10.2217/fon-2017-0218. Epub 2017 Aug 24. Review.

PMID:
28835114
17.

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

Hammers HJ, Plimack ER, Infante JR, Rini BI, McDermott DF, Lewis LD, Voss MH, Sharma P, Pal SK, Razak ARA, Kollmannsberger C, Heng DYC, Spratlin J, McHenry MB, Amin A.

J Clin Oncol. 2017 Dec 1;35(34):3851-3858. doi: 10.1200/JCO.2016.72.1985. Epub 2017 Jul 5.

PMID:
28678668
18.

Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?

Gordon MJ, Lewis LD, Brown JR, Danilov AV.

Expert Rev Hematol. 2017 Aug;10(8):707-718. doi: 10.1080/17474086.2017.1350166. Epub 2017 Jul 10. Review.

PMID:
28664772
19.

Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.

Abou-Alfa GK, Lewis LD, LoRusso P, Maitland M, Chandra P, Cheeti S, Colburn D, Williams S, Simmons B, Graham RA.

Cancer Chemother Pharmacol. 2017 Jul;80(1):29-36. doi: 10.1007/s00280-017-3315-8. Epub 2017 May 18.

20.

Methotrexate encephalopathy: Two cases in adult cancer patients, who recovered with pathophysiologically based therapy.

Coker SA, Pastel DA, Davis MC, Bengtson EM, Fadul CE, Lewis LD.

SAGE Open Med Case Rep. 2017 May 4;5:2050313X17706875. doi: 10.1177/2050313X17706875. eCollection 2017.

21.

Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.

Hampsch RA, Shee K, Bates D, Lewis LD, Désiré L, Leblond B, Demidenko E, Stefan K, Huang YH, Miller TW.

Oncotarget. 2017 Mar 28;8(13):21806-21817. doi: 10.18632/oncotarget.15586.

22.

Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS.

Kim KP, Parise RA, Holleran JL, Lewis LD, Appleman L, van Erp N, Morris MJ, Beumer JH.

J Pharm Biomed Anal. 2017 May 10;138:197-205. doi: 10.1016/j.jpba.2017.02.018. Epub 2017 Feb 13.

23.

A Pharmacokinetic and Safety Study of Trebananib, an Fc-Fusion Peptibody, in Patients With Advanced Solid Tumors and Varying Degrees of Renal Dysfunction.

Wu B, Lewis LD, Harvey RD, Rasmussen E, Gamelin E, Sun YN, Friberg G, Koyner JL, Dowlati A, Maitland ML.

Clin Pharmacol Ther. 2017 Aug;102(2):313-320. doi: 10.1002/cpt.617. Epub 2017 Jun 9.

PMID:
28074547
24.

Immune modulation associated with vascular endothelial growth factor (VEGF) blockade in patients with glioblastoma.

Thomas AA, Fisher JL, Hampton TH, Christensen BC, Tsongalis GJ, Rahme GJ, Whipple CA, Steel SE, Davis MC, Gaur AB, Lewis LD, Ernstoff MS, Fadul CE.

Cancer Immunol Immunother. 2017 Mar;66(3):379-389. doi: 10.1007/s00262-016-1941-3. Epub 2016 Dec 9.

PMID:
27942839
25.

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.

Clark JI, Wong MKK, Kaufman HL, Daniels GA, Morse MA, McDermott DF, Agarwala SS, Lewis LD, Stewart JH, Vaishampayan U, Curti B, Gonzalez R, Lutzky J, Rudraptna V, Cranmer LD, Jeter JM, Hauke RJ, Miletello G, Milhem MM, Amin A, Richart JM, Fishman M, Hallmeyer S, Patel SP, Van Veldhuizen P, Agarwal N, Taback B, Treisman JS, Ernstoff MS, Perritt JC, Hua H, Rao TB, Dutcher JP, Aung S.

Clin Genitourin Cancer. 2017 Feb;15(1):31-41.e4. doi: 10.1016/j.clgc.2016.10.008. Epub 2016 Oct 29.

26.

Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.

Agarwal SK, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M, Chien D, Lewis LD, Wong SL.

Br J Clin Pharmacol. 2017 Apr;83(4):846-854. doi: 10.1111/bcp.13175. Epub 2017 Jan 18.

27.

Fast fMRI can detect oscillatory neural activity in humans.

Lewis LD, Setsompop K, Rosen BR, Polimeni JR.

Proc Natl Acad Sci U S A. 2016 Oct 25;113(43):E6679-E6685. Epub 2016 Oct 11.

28.

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103.

Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, Smith SM, Czuczman M, Davids MS, Levine E, Lewis LD, Smith SE, Bartlett NL, Leonard JP, Cheson BD.

Blood. 2016 Nov 24;128(21):2510-2516. Epub 2016 Oct 3.

29.

A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.

Danilov AV, Lewis LD, Lansigan F, Roudaia L, Findley DL, Jones SY, Highhouse B, Beaulieu BB, Brown JR.

Br J Haematol. 2017 Sep;178(5):820-823. doi: 10.1111/bjh.14171. Epub 2016 Jul 5. No abstract available.

30.

S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction.

Chang AT, Bertino JS Jr, Nafziger AN, Kashuba AD, Turpault S, Lewis LD, Ma JD.

Ther Drug Monit. 2016 Jun;38(3):383-7. doi: 10.1097/FTD.0000000000000277.

PMID:
26818625
31.

Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer.

Yang W, Hosford SR, Dillon LM, Shee K, Liu SC, Bean JR, Salphati L, Pang J, Zhang X, Nannini MA, Demidenko E, Bates D, Lewis LD, Marotti JD, Eastman AR, Miller TW.

Clin Cancer Res. 2016 May 1;22(9):2250-60. doi: 10.1158/1078-0432.CCR-15-2276. Epub 2016 Jan 5.

32.

Thalamic reticular nucleus induces fast and local modulation of arousal state.

Lewis LD, Voigts J, Flores FJ, Schmitt LI, Wilson MA, Halassa MM, Brown EN.

Elife. 2015 Oct 13;4:e08760. doi: 10.7554/eLife.08760.

33.

Treatment of pain in fibromyalgia patients with testosterone gel: Pharmacokinetics and clinical response.

White HD, Brown LA, Gyurik RJ, Manganiello PD, Robinson TD, Hallock LS, Lewis LD, Yeo KT.

Int Immunopharmacol. 2015 Aug;27(2):249-56. doi: 10.1016/j.intimp.2015.05.016. Epub 2015 May 21.

34.

Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivo.

Bates DJ, Lewis LD, Eastman A, Danilov AV.

Br J Clin Pharmacol. 2015 Sep;80(3):493-501. doi: 10.1111/bcp.12624. Epub 2015 May 19.

35.

Tumor cell targeting by iron oxide nanoparticles is dominated by different factors in vitro versus in vivo.

NDong C, Tate JA, Kett WC, Batra J, Demidenko E, Lewis LD, Hoopes PJ, Gerngross TU, Griswold KE.

PLoS One. 2015 Feb 19;10(2):e0115636. doi: 10.1371/journal.pone.0115636. eCollection 2015.

36.

Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.

Devriese LA, Witteveen PE, Mergui-Roelvink M, Smith DA, Lewis LD, Mendelson DS, Bang YJ, Chung HC, Dar MM, Huitema AD, Beijnen JH, Voest EE, Schellens JH.

Br J Clin Pharmacol. 2015 Aug;80(2):253-66. doi: 10.1111/bcp.12606. Epub 2015 May 20.

37.

Clinical trial simulation to evaluate population pharmacokinetics and food effect: capturing abiraterone and nilotinib exposures.

Li CH, Sherer EA, Lewis LD, Bies RR.

J Clin Pharmacol. 2015 May;55(5):556-62. doi: 10.1002/jcph.449. Epub 2015 Feb 4.

38.

Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).

Beumer JH, Owzar K, Lewis LD, Jiang C, Holleran JL, Christner SM, Blum W, Devine S, Kolitz JE, Linker C, Vij R, Alyea EP, Larson RA, Ratain MJ, Egorin MJ.

Cancer Chemother Pharmacol. 2014 Nov;74(5):927-38. doi: 10.1007/s00280-014-2571-0. Epub 2014 Aug 28.

39.

Development of a rapid clinical TPMT genotyping assay.

Burchard PR, Abou Tayoun AN, Lefferts JA, Lewis LD, Tsongalis GJ, Cervinski MA.

Clin Biochem. 2014 Oct;47(15):126-9. doi: 10.1016/j.clinbiochem.2014.07.088. Epub 2014 Aug 2.

PMID:
25093923
40.

Vatalanib population pharmacokinetics in patients with myelodysplastic syndrome: CALGB 10105 (Alliance).

Wang X, Owzar K, Gupta P, Larson RA, Mulkey F, Miller AA, Lewis LD, Hurd D, Vij R, Ratain MJ, Murry DJ; Alliance for Clinical Trials in Oncology.

Br J Clin Pharmacol. 2014 Nov;78(5):1005-13. doi: 10.1111/bcp.12427.

41.

Editors' report, November 2013.

Somogyi AA, Lewis LD, Cohen AF, Flockhart DA, Ferro A, Loke YK, Ritter JM.

Br J Clin Pharmacol. 2014 Mar;77(3):401-2. doi: 10.1111/bcp.12317. No abstract available.

42.

Editors' pick 2013.

Ferro A, Loke YK, Lewis LD, Somogyi A, Cohen AF, Ritter JM.

Br J Clin Pharmacol. 2014 Feb;77(2):228-32. doi: 10.1111/bcp.12303. No abstract available.

43.

Differential requirement for NMDAR activity in SAP97β-mediated regulation of the number and strength of glutamatergic AMPAR-containing synapses.

Liu M, Lewis LD, Shi R, Brown EN, Xu W.

J Neurophysiol. 2014 Feb;111(3):648-58. doi: 10.1152/jn.00262.2013. Epub 2013 Nov 13.

44.

A phase I, dose-escalation study of cyclical weekly oral temozolomide and weekly PEG-interferon alpha-2b in patients with refractory or advanced solid tumours.

Coker SA, Dandamudi UB, Beelen AP, Crosby NA, Fisher JL, Obrocea M, Ernstoff MS, Lewis LD.

J Chemother. 2013 Dec;25(6):362-8. doi: 10.1179/1973947813Y.0000000102. Epub 2013 Dec 6.

PMID:
24093213
45.
46.

Local cortical dynamics of burst suppression in the anaesthetized brain.

Lewis LD, Ching S, Weiner VS, Peterfreund RA, Eskandar EN, Cash SS, Brown EN, Purdon PL.

Brain. 2013 Sep;136(Pt 9):2727-37. doi: 10.1093/brain/awt174. Epub 2013 Jul 25.

47.

Manipulating the apoptotic pathway: potential therapeutics for cancer patients.

Bates DJ, Lewis LD.

Br J Clin Pharmacol. 2013 Sep;76(3):381-95. doi: 10.1111/bcp.12193. Review.

48.

Encoding through patterns: regression tree-based neuronal population models.

Haslinger R, Pipa G, Lewis LD, Nikolić D, Williams Z, Brown E.

Neural Comput. 2013 Aug;25(8):1953-93. doi: 10.1162/NECO_a_00464. Epub 2013 Apr 22.

PMID:
23607564
49.

A proof of principle clinical trial to determine whether conjugated linoleic acid modulates the lipogenic pathway in human breast cancer tissue.

McGowan MM, Eisenberg BL, Lewis LD, Froehlich HM, Wells WA, Eastman A, Kuemmerle NB, Rosenkrantz KM, Barth RJ Jr, Schwartz GN, Li Z, Tosteson TD, Beaulieu BB Jr, Kinlaw WB.

Breast Cancer Res Treat. 2013 Feb;138(1):175-83. doi: 10.1007/s10549-013-2446-9. Epub 2013 Feb 16.

50.

Establishment of a CYP2C19 genotyping assay for clinical use.

Cervinski MA, Schwab MC, Lefferts JA, Lewis LD, Lebel KA, Tyropolis AM, Pflueger SM, Tsongalis GJ.

Am J Clin Pathol. 2013 Feb;139(2):202-7. doi: 10.1309/AJCP9K2KDOCPCBSV.

PMID:
23355205

Supplemental Content

Loading ...
Support Center